|
1
|
Chen G, Liu N, Zhou A, Tang C, Ma D and
Tang J: The role of hypertension-related gene in aortic vascular
smooth muscle cells from mice and rats. Chin Med J (Engl).
114:833–836. 2001.PubMed/NCBI
|
|
2
|
Guo X, Chen KH, Guo Y, et al: Mitofusin 2
triggers vascular smooth muscle cell apoptosis via mitochondrial
death pathway. Circ Res. 101:1113–1122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karbowski M, Lee YJ, Gaume B, Jeong SY,
Frank S, Nechushtan A, Santel A, Fuller M, Smith CL and Youle RJ:
Spatial and temporal association of Bax with mitochondrial fission
sites, Drp1 and Mfn2 during apoptosis. J Cell Biol. 159:931–938.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D,
Li P, Qiu X, Wen S, Xiao RP and Tang J: Dysregulation of HSG
triggers vascular proliferative disorders. Nat Cell Biol.
6:872–883. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang W, Lu J, Zhu F, Wei J, Jia C, Zhang
Y, Zhou L, Xie H and Zheng S: Pro-apoptotic and anti-proliferative
effects of mitofusin-2 via Bax signaling in hepatocellular
carcinoma cells. Med Oncol. 29:70–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J,
Chen G and Zheng S: Anti-tumour efficacy of mitofusin-2 in urinary
bladder carcinoma. Med Oncol. 28(Suppl 1): S373–S380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang GE, Jin HL, Lin XK, Chen C, Liu XS,
Zhang Q and Yu JR: Anti-tumor effects of mfn2 in gastric cancer.
Int J Mol Sci. 14:13005–13021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
MacGregor JI and Jordan VC: Basic guide to
the mechanisms of antiestrogen action. Pharmacol Rev. 50:151–196.
1998.PubMed/NCBI
|
|
9
|
Sommer S and Fuqua SA: Estrogen receptor
and breast cancer. Semin Cancer Biol. 11:339–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nilsson S, Mäkelä S, Treuter E, Tujague M,
Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M and
Gustafsson JA: Mechanisms of estrogen action. Physiol Rev.
81:1535–1565. 2001.PubMed/NCBI
|
|
11
|
Speirs V, Carder PJ, Lane S, Dodwell D,
Lansdown MR and Hanby AM: Oestrogen receptor beta: what it means
for patients with breast cancer. Lancet Oncol. 5:174–181. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma L, Liu Y, Geng C, Qi X and Jiang J:
Estrogen receptor β inhibits estradiol-induced proliferation and
migration of MCF-7 cells through regulation of mitofusin 2. Int J
Oncol. 42:1993–2000. 2013.PubMed/NCBI
|
|
13
|
Zhang D, Ma C, Li S, Ran Y, Chen J, Lu P,
Shi S and Zhu D: Effect of Mitofusin 2 on smooth muscle cells
proliferation in hypoxic pulmonary hypertension. Microvasc Res.
84:286–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fabregat I, Roncero C and Fernandez M:
Survival and apoptosis: A dysregulated balance in liver cancer.
Liver Int. 27:155–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guicciardi ME and Gores GJ: Apoptosis: A
mechanism of acute and chronic liver injury. Gut. 54:1024–1033.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Braathen GJ, Sand JC, Lobato A, Høyer H
and Russell MB: Mfn2 point mutations occur in 3.4% of
Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT
families. BMC Med Genet. 11:482010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bagchi A and Mills AA: The quest for the
1p36 tumor suppressor. Cancer Res. 68:2551–2556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Brito OM and Scorrano L: Mitofusin 2: A
mitochondria-shaping protein with signaling roles beyond fusion.
Antioxid Redox Signal. 10:621–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Westermann B: Molecular machinery of
mitochondrial fusion and fission. J Biol Chem. 283:13501–13505.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirai K, Hayashi T, Chan PH, Zeng J, Yang
GY, Basus VJ, James TL and Litt L: PI3K inhibition in neonatal rat
brain slices during and after hypoxia reduces phospho-Akt and
increases cytosolic cytochrome c and apoptosis. Brain Res Mol Brain
Res. 124:51–61. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saini KS, Loi S, de Azambuja E,
Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and
Piccart-Gebhart MJ: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK
pathways in the treatment of breast cancer. Cancer Treat Rev.
39:935–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W,
Wang A, Seong YS and Bae I: Inhibition of the PI3K/AKT pathway
potentiates cytotoxicity of EGFR kinase inhibitors in
triple-negative breast cancer cells. J Cell Mol Med. 17:648–656.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pande S, Browne G, Padmanabhan S, Zaidi
SK, Lian JB, van Wijnen AJ, Stein JL and Stein GS: Oncogenic
cooperation between PI3K/Akt signaling and transcription factor
Runx2 promotes the invasive properties of metastatic breast cancer
cells. J Cell Physiol. 228:1784–1792. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calleros L, Sánchez-Hernández I, Baquero
P, Toro MJ and Chiloeches A: Oncogenic Ras, but not (V600E) B-RAF,
protects from cholesterol depletion-induced apoptosis through the
PI3K/AKT pathway in colorectal cancer cells. Carcinogenesis.
30:1670–1677. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signaling pathways: role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsubaki M, Satou T, Itoh T, Imano M, Ogaki
M, Yanae M and Nishida S: Reduction of metastasis, cell invasion
and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced
blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl
Pharmacol. 259:402–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
